TERN
Terns Pharmaceuticals Inc
NASDAQ · Pharmaceuticals
$37.77
+2.43 (+6.88%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 649.21M | 641.61M | 607.21M |
| Net Income | 208.45M | 199.92M | 172.59M |
| EPS | — | — | — |
| Profit Margin | 32.1% | 31.2% | 28.4% |
| Rev Growth | -4.4% | +22.1% | +20.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 481.86M | 583.65M | 496.46M |
| Total Equity | 2.77B | 2.41B | 2.51B |
| D/E Ratio | 0.17 | 0.24 | 0.20 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 253.94M | 217.05M | 208.00M |
| Free Cash Flow | 152.21M | 227.98M | 177.76M |